Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 Jun;35(6):1745-1750.
doi: 10.1038/s41375-020-01022-2. Epub 2020 Sep 18.

Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome

Marlijn Hoeks  1   2   3 , Tim Bagguley  4 , Corine van Marrewijk  5 , Alex Smith  4 , David Bowen  6 , Dominic Culligan  7 , Seye Kolade  8 , Argiris Symeonidis  9 , Hege Garelius  10 , Michail Spanoudakis  11   12 , Saskia Langemeijer  5 , Rian Roelofs  13 , Erwin Wiegerinck  13 , Aurelia Tatic  14 , Sally Killick  15 , Panagiotis Panagiotidis  16 , Oana Stanca  17 , Eva Hellström-Lindberg  18 , Jaroslav Cermak  19 , Melanie van der Klauw  20 , Hanneke Wouters  20 , Marian van Kraaij  5 , Nicole Blijlevens  5 , Dorine W Swinkels  13 , Theo de Witte  21 ; EUMDS Registry Participants
Collaborators, Affiliations
Observational Study

Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome

Marlijn Hoeks et al. Leukemia. 2021 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

CvM: project manager of the EUMDS Registry, is funded by the EUMDS and MDS-RIGHT project budget; ASm: research funding from Novartis, Cilag-Janssen, and Boehringer Ingelheim; ASy: honoraria and consulting fees from Amgen, Celgene/GenesisPharma, Genzyme/Sanofi, Gilead, Janssen-Cilag, Pfizer, MSD, and Novartis; HG: honoraria from Celgene, Novartis, and Alexion; SK: honoraria from Novartis, Jazz, and Celgene; EH-L: research funding from Celgene; NB: research funding from Novartis, Bristol Meyer Squibb, Pfizer, Ariad, MSD, Astellas, Xenikos, and Celgene, educational grant from Novartis, Celgene, and Janssen-Cilag; DWS: paid employee of RadboudUMC, which offers hepcidin measurements via Hepcidinanalysis.com at a fee for service basis; TdW: research funding from Amgen, Celgene, and Novartis, as project coordinator EUMDS. The other authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1. Kaplan–Meier curve overall survival stratified by labile plasma iron above or below the lower limit of detection and transfusion status as time-dependent variables.
LPI labile plasma iron, LLOD lower limit of detection, TI transfusion-independent, TD transfusion-dependent.
See this image and copyright information in PMC

References

    1. Cazzola M, Della Porta MG, Malcovati L. Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2008;1:166–75. doi: 10.1182/asheducation-2008.1.166. - DOI - PubMed
    1. Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005;23:7594–603. doi: 10.1200/JCO.2005.01.7038. - DOI - PubMed
    1. Leitch HA, Fibach E, Rachmilewitz E. Toxicity of iron overload and iron overload reduction in the setting of hematopoietic stem cell transplantation for hematologic malignancies. Crit Rev Oncol Hematol. 2017;113:156–70. doi: 10.1016/j.critrevonc.2017.03.002. - DOI - PubMed
    1. Shenoy N, Vallumsetla N, Rachmilewitz E, Verma A, Ginzburg Y. Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome. Blood. 2014;124:873–81. doi: 10.1182/blood-2014-03-563221. - DOI - PMC - PubMed
    1. de Swart L, Reiniers C, Bagguley T, van Marrewijk C, Bowen D, Hellström-Lindberg E, et al. Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes. Haematologica. 2018;103:69–79. doi: 10.3324/haematol.2017.171884. - DOI - PMC - PubMed

Publication types